Literature DB >> 20847993

The efficacy of platelet-rich plasma in grafted maxillae. A randomised clinical trial.

Mohamed Badr1, Paul Coulthard, Rami Alissa, Richard Oliver.   

Abstract

PURPOSE: The aim of this randomised, controlled, parallel-group clinical trial was to evaluate the clinical effect of platelet-rich plasma (PRP) on bone graft healing and implant integration in iliac crest grafted maxillae.
MATERIALS AND METHODS: Twenty-two consenting patients were randomised to PRP (13 patients) and control (9 patients) groups. Both groups received onlays and 16 patients had their maxillary sinus grafted with particulate bone (lateral window approach) with iliac crest bone grafts. Autologous platelet concentrates were prepared from the patients' blood and autologous thrombin was produced. PRP was mixed with the test group bone grafts. Outcome measures were implant integration, implant stability, soft tissue healing, graft resorption, and donor and recipient site complications. Implant stability measurements were recorded at placement and exposure using a resonance frequency analysis device. Patients were followed up to abutment connection. Multiple linear regression analyses using robust standard error were performed, taking the patient as the unit of measurement. The t test was also used where appropriate.
RESULTS: One bone graft failed in the PRP group and regrafting was required. No statistically significant differences were observed for soft tissue healing indices (P = 0.4) and mean graft resorption (P = 0.5) between groups. All implants were found clinically integrated at time of exposure. No statistically significant differences in implant stability were observed between groups at implant placement (P = 0.059) and exposure (P = 0.1). Using a post-hoc analysis, posterior implants in the PRP group showed statistically significantly higher stability values (61 ± 2.6) than anterior implants (60 ± 2.4) at implant placement (mean difference -0.95, P = 0.04). However, this difference was not clinically significant.
CONCLUSION: No appreciable clinical effect could be observed when using PRP with autologous iliac crest bone graft in the maxilla.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847993

Source DB:  PubMed          Journal:  Eur J Oral Implantol        ISSN: 1756-2406            Impact factor:   3.123


  6 in total

1.  SIMTI recommendations on blood components for non-transfusional use.

Authors:  Giuseppe Aprili; Giorgio Gandini; Roberto Guaschino; Laura Mazzucco; Laura Salvaneschi; Stefania Vaglio
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 2.  Platelet-Rich Plasma Promotes Axon Regeneration, Wound Healing, and Pain Reduction: Fact or Fiction.

Authors:  Damien P Kuffler
Journal:  Mol Neurobiol       Date:  2015-06-06       Impact factor: 5.590

3.  Platelet gel: applications in dental regenerative surgery.

Authors:  Franco Forni; Massimo Marzagalli; Patrizia Tesei; Alessandra Grassi
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

4.  Morphological Characteristics and Correction of Long Tubular Bone Regeneration under Chronic Hyperglycemia Influence.

Authors:  Yevhenii S Dudchenko; Olena S Maksymova; Vasyl S Pikaliuk; Dmytro V Muravskyi; Ludmila I Kyptenko; Gennadii F Tkach
Journal:  Anal Cell Pathol (Amst)       Date:  2020-04-06       Impact factor: 2.916

Review 5.  Does PRP enhance bone integration with grafts, graft substitutes, or implants? A systematic review.

Authors:  Alice Roffi; Giuseppe Filardo; Elizaveta Kon; Maurilio Marcacci
Journal:  BMC Musculoskelet Disord       Date:  2013-11-21       Impact factor: 2.362

6.  Effect of Blood Component Coatings of Enosseal Implants on Proliferation and Synthetic Activity of Human Osteoblasts and Cytokine Production of Peripheral Blood Mononuclear Cells.

Authors:  Lucie Himmlova; Dana Kubies; Hana Hulejova; Jirina Bartova; Tomas Riedel; Jana Stikarova; Jiri Suttnar; Vlasta Pesakova
Journal:  Mediators Inflamm       Date:  2016-08-29       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.